Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer

Cancer Research

Volumn 65, Issue 15, 2005, Pages 7000-7006

  Coleman, Sharon ^a   Clayton, Aled ^a   Mason, Malcolm D ^a   Jasani, Bharat ^b   Adams, Malcolm ^c   Tabi, Zsuzsanna ^a,b  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Velindre NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CD8 ANTIGEN; CYTOKINE; EPITOPE; PACLITAXEL; SYNTHETIC PEPTIDE; TUMOR MARKER; VIRUS PROTEIN;

ADVANCED CANCER; ANTIGEN SPECIFICITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CAUCASIAN; CELL FUNCTION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IN VITRO STUDY; LONGITUDINAL STUDY; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SYSTEMIC THERAPY; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD45; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; IMMUNOLOGIC MEMORY; L-SELECTIN; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTORS, CHEMOKINE;

EID: 14844293666     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3792     Document Type: Article

References (35)

1. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
2. + tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004;35:808-16.
3. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
4. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6.
5. Dudley M, Wunderlich J, Robbins P, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
6. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002;99: 16168-73.
7. + T-cell responses are impaired in multiple myeloma. Br J Haematol 2003;121: 842-8.
8. Scrivener S, Goddard R, Kaminski E, Prentice A. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:383-9.
9. Batrla R, Linnebacher M, Rudy W, et al. CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions. Cancer Res 2002;62:2052-7.
10. Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol 2003;3: 1061-71.
11. Yee C, Greenberg P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2002;2:409-19.
12. Rentzsch C, Kayser S, Stumm S, et al. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res 2003;9:4376-86.
13. - antitumor T cells. Cancer Res 2004;64:2175-82.
14. Cannon M, Santin A, O'Brien T. Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol 2004;16:87-92.
15. Currier J, Kuta E, Turk E, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157-72.
16. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 2002;99:2913-21.
17. Rustin G, Nelstrop A, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14: 1545-51.
18. Rustin G, Bast R, Kelloff G, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004;10:3919-26.
19. Romero P, Cerottini J, Speiser D. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 2004;53:249-55.
20. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002;25:97-138.
21. Luft T, Pang K, Thomas E, et al. Type 1 IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161:1947-53.
22. Ito T, Amakawa R, Inaba M, et al. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001;166:2961-9.
23. + T cell responses against human tumor antigens. J Immunol 2004;172: 5363-70.
24. Wesa A, Galy A. IL-1β induces dendritic cells to produce IL-12. Int Immunol 2001;13:1053-61.
25. + dendritic cells and is up-regulated by IL-1β. J Immunol 2001;167:1989-95.
26. Hsiao Y, Liao K, Hung S, Chu R. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-β1 and restores the lymphokine-activated killing activity. J Immunol 2004;172:1508-14.
27. + T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6.
28. Kuhweide R, Van Damme J, Lorre K, et al. Accessory cell-derived helper signals in human T-cell activation with phytohemagglutinin: induction of interleukin 2-responsiveness by interleukin 6, and production of interleukin 2 by interleukin 1. Cytokine 1990;2:45-54.
29. Maecker H, Dunn H, Suni M, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001;255:27-40.
30. Sekine H, Hayes D, Ohno T, et al. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol 1985;3: 1355-63.
31. Macciò A, Lai P, Santona M, et al. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998;69:248-52.
32. Wang H, Xie X, Lu W et al. Ovarian carcinoma cells inhibit T cell proliferation: suppression of IL-2 receptor β and γ expression and their JAK-STAT signaling pathway. Life Sci 2004;74:1739-49.
33. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
34. Chao C, Jensen R, Dailey M. Mechanisms of L-selectin regulation by activated T cells. J Immunol 1997;159: 1686-94.
35. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005;105:241-50.